Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen

References

• Prescription cost analysis for England./person-group>: 1998–2006. Department of Health. Available at: http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
   Google Scholar
• Prescription cost analysis for Scotland./person-group>: 2001–2006. Scottish Health Statistics. Available at: http://www.isdscotland.org/isd/info3.jsp?pContentID=2241&p_applic=CCC&p_service=Content.show&
   Google Scholar
• Prescription cost analysis for Wales./person-group>: 2001–2006. Health of Wales Information Service (Publicly available – provided on request to the author)
   Google Scholar
• Prescription cost analysis for Northern Ireland./person-group>: 2000–2006. Central Services Agency Available at: http://www.centralservicesagency.com/display/statistics
   Google Scholar
• Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007;61:15–23
   Google Scholar
• Minas R. Statin utilization – recognizing the role of the invisible hand. Int J Clin Pract 2007;61:3–6
   PubMed Web of Science ®Google Scholar
• Moon JC, Bogle RG. How to lose a billion pounds. Int J Clin Pract 2007;61:2–3
   PubMed Web of Science ®Google Scholar
• National Audit Office./person-group>. Prescribing costs in primary care. London 2007. Available at: http://www.nao.org.uk/publications/nao_reports/06–07/0607454.pdf
   Google Scholar
• Department of Health Health Survey for England./person-group> 2003 London 2004. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_4098712
   Google Scholar
• Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418–26
   PubMed Web of Science ®Google Scholar
• Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005;5:131–40
   PubMedGoogle Scholar
• Baguet JP, Legallicier B, Auquier P, Robitail S. Updated metaanalytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Invest 2007;27:735–53
   PubMed Web of Science ®Google Scholar
• Ram CV./person-group>. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004;6:569–77
   PubMedGoogle Scholar
• MIMS July 2007. Haymarket Medical Publishing
   Google Scholar
• Van Wijk BL, Klungel OH, Heerdink ER, de Boer BA. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006;40:15–20
   Google Scholar
• Van Wijk BL, Klungel OH, Heerdink ER, de Boer BA. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004;22:1831–7
   Google Scholar
• Enlund H, Jokisalo E, Wallenius S, Korhonen M. Patient-perceived problems, compliance, and the outcome of hypertension treatment. Pharm World Sci 2001;23:60–4
   PubMed Web of Science ®Google Scholar
• Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243–9
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–31
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   PubMed Web of Science ®Google Scholar
• Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3: 283–91, 318
   Google Scholar
• Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan [Irbesartan/Losartan Study Investigators]. Clin Ther 1998;20:398–409
   PubMed Web of Science ®Google Scholar
• Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187–95
   PubMedGoogle Scholar
• Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension [Losartan Trial Investigators]. Clin Ther 2000;22:1186–203
   PubMed Web of Science ®Google Scholar